Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Prostatic neoplasms | D011471 | — | C61 | — | 1 | — | — | — | 1 |
Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | — | — | — | 1 |
Non-small-cell lung carcinoma | D002289 | — | — | — | 1 | — | — | — | 1 |
Inflammatory breast neoplasms | D058922 | — | — | 1 | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Colorectal neoplasms | D015179 | — | — | 1 | — | — | — | — | 1 |
Drug common name | GRAPIPRANT |
INN | grapiprant |
Description | Grapiprant, sold under the brand name Galliprant, is a small molecule drug that belongs in the piprant class. This analgesic and anti-inflammatory drug is primarily used as a pain relief for mild to moderate inflammation related to osteoarthritis in dogs. Grapiprant has been approved by the FDA's Center for Veterinary Medicine and was categorized as a non-cyclooxygenase inhibiting non-steroidal anti-inflammatory drug (NSAID) in March 2016.
|
Classification | Small molecule |
Drug class | prostaglandin receptor antagonists, non prostinoid structure |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CCc1nc2c(C)nc(C)cc2n1-c1ccc(CCNC(=O)NS(=O)(=O)c2ccc(C)cc2)cc1 |
PDB | — |
CAS-ID | 415903-37-6 |
RxCUI | — |
ChEMBL ID | CHEMBL3039498 |
ChEBI ID | — |
PubChem CID | 11677589 |
DrugBank | DB12836 |
UNII ID | J9F5ZPH7NB (ChemIDplus, GSRS) |